GB2525743A - Immunosignaturing: a path to early diagnosis and health monitoring - Google Patents

Immunosignaturing: a path to early diagnosis and health monitoring Download PDF

Info

Publication number
GB2525743A
GB2525743A GB1504970.3A GB201504970A GB2525743A GB 2525743 A GB2525743 A GB 2525743A GB 201504970 A GB201504970 A GB 201504970A GB 2525743 A GB2525743 A GB 2525743A
Authority
GB
United Kingdom
Prior art keywords
health
health monitoring
molecules
immunosignaturing
path
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1504970.3A
Other languages
English (en)
Other versions
GB201504970D0 (en
Inventor
Stephen Albert Johnston
Philip Stafford
Neal Woodbury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Arizona's Public Universities
Original Assignee
University of Arizona
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona, Arizona's Public Universities filed Critical University of Arizona
Publication of GB201504970D0 publication Critical patent/GB201504970D0/en
Publication of GB2525743A publication Critical patent/GB2525743A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00722—Nucleotides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00729—Peptide nucleic acids [PNA]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1504970.3A 2012-08-29 2013-08-29 Immunosignaturing: a path to early diagnosis and health monitoring Withdrawn GB2525743A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261694598P 2012-08-29 2012-08-29
PCT/US2013/057373 WO2014036312A2 (en) 2012-08-29 2013-08-29 Immunosignaturing: a path to early diagnosis and health monitoring

Publications (2)

Publication Number Publication Date
GB201504970D0 GB201504970D0 (en) 2015-05-06
GB2525743A true GB2525743A (en) 2015-11-04

Family

ID=50184639

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1504970.3A Withdrawn GB2525743A (en) 2012-08-29 2013-08-29 Immunosignaturing: a path to early diagnosis and health monitoring

Country Status (8)

Country Link
US (2) US20140087963A1 (https=)
EP (1) EP2890984B1 (https=)
JP (2) JP6463678B2 (https=)
CN (2) CN104781668B (https=)
AU (2) AU2013308682A1 (https=)
CA (1) CA2882801C (https=)
GB (1) GB2525743A (https=)
WO (1) WO2014036312A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP2430574A1 (en) 2009-04-30 2012-03-21 Patientslikeme, Inc. Systems and methods for encouragement of data submission in online communities
WO2014062981A1 (en) * 2012-10-17 2014-04-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University In situ chemical patterning
JP6503966B2 (ja) * 2015-08-05 2019-04-24 株式会社島津製作所 多変量解析結果表示装置
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
US20180284114A1 (en) * 2015-10-02 2018-10-04 Arizona Board Of Regents On Behalf Of Arizona State University Methods for processing biopolymeric arrays
EP3373950B1 (en) 2015-11-11 2024-05-01 Serimmune Inc. Methods and compositions for assessing antibody specificities
WO2017223117A1 (en) * 2016-06-20 2017-12-28 Healthtell Inc. Methods for diagnosis and treatment of autoimmune diseases
AU2017281039A1 (en) 2016-06-20 2019-01-24 Healthtell Inc. Methods for differential diagnosis of autoimmune diseases
WO2018089554A1 (en) 2016-11-09 2018-05-17 Healthtell Inc. Pre-assembled, protected, chemically stable, chemoselective linkers
AU2017359450A1 (en) 2016-11-09 2019-05-30 HealthTell, Inc. Coatings with tunable amine density
AU2017357818A1 (en) 2016-11-11 2019-05-30 HealthTell, Inc. Methods for identifying candidate biomarkers
EP3544737B1 (en) 2016-11-28 2025-04-23 Arizona Board of Regents on behalf of Arizona State University Methods related to continuous flow droplet reaction
WO2018144571A2 (en) 2017-01-31 2018-08-09 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic to distinguish bacterial infections
JP2020522479A (ja) 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 個別化された癌ワクチンを作製する方法
WO2019055879A2 (en) 2017-09-15 2019-03-21 PatientsLikeMe Inc. SYSTEMS AND METHODS FOR COLLECTING AND ANALYZING COMPLETE MEDICAL INFORMATION
US12025615B2 (en) * 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
US11205139B2 (en) 2018-08-06 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Computational analysis to predict molecular recognition space of monoclonal antibodies through random-sequence peptide arrays
US11894139B1 (en) 2018-12-03 2024-02-06 Patientslikeme Llc Disease spectrum classification
CA3135206A1 (en) 2019-04-29 2020-11-05 Pierre Indermuhle Methods and systems for integrated on-chip single-molecule detection
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
EP4153999A1 (en) * 2020-05-19 2023-03-29 Laboratory Corporation of America Holdings Methods and systems for quantitative detection of antibodies
WO2023056466A1 (en) * 2021-10-01 2023-04-06 Arizona Board Of Regents On Behalf Of Arizona State University Machine learning approaches to enhance disease diagnostics
CN114512244B (zh) * 2021-12-09 2025-05-06 广东省人民医院 一种基于深度学习的感染类疾病无创诊断方法
US12091715B2 (en) 2022-04-21 2024-09-17 Paragon Genomics, Inc. Methods and compositions for reducing base errors of massive parallel sequencing using triseq sequencing
US11680293B1 (en) 2022-04-21 2023-06-20 Paragon Genomics, Inc. Methods and compositions for amplifying DNA and generating DNA sequencing results from target-enriched DNA molecules
US20240266008A1 (en) * 2023-02-01 2024-08-08 Unlearn.AI, Inc. Systems and Methods for Designing Augmented Randomized Trials

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020678A1 (en) * 2002-10-30 2007-01-25 Dana Ault-Riche Methods for producing polypeptide-tagged collections and capture systems containing the tagged polypeptides
WO2011109440A1 (en) * 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
US20120190574A1 (en) * 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759774A (en) * 1988-05-18 1998-06-02 Cobe Laboratories, Inc. Method of detecting circulating antibody types using dried or lyophilized cells
US5449754A (en) * 1991-08-07 1995-09-12 H & N Instruments, Inc. Generation of combinatorial libraries
US6346423B1 (en) * 1999-07-16 2002-02-12 Agilent Technologies, Inc. Methods and compositions for producing biopolymeric arrays
US20040048252A1 (en) * 2000-02-03 2004-03-11 Frank Breitling Method and Device For the Synthesis and the Analysis of Suppert-Bound Arrays of Oligomers, Especially of Primer Pairs for PCR, as well as Oligomer-Carrying Supports
CN1438324A (zh) * 2003-03-10 2003-08-27 东南大学 一种寡聚核苷酸微阵列芯片及其制备方法
US20050255491A1 (en) * 2003-11-13 2005-11-17 Lee Frank D Small molecule and peptide arrays and uses thereof
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
DE102005060920A1 (de) * 2005-12-18 2007-06-21 Charité - Universitätsmedizin Berlin Peptide für die Wechselwirkung mit alpha-helikalen Coiled-Coil-Strukturen und/oder Coiled-Coil-Sequenzen, davon abgeleitete Mittel und ihre Verwendung
US20100210478A1 (en) * 2006-06-29 2010-08-19 Xiaolian Gao Make and use of surface molecules of varied densities
JP2008063285A (ja) * 2006-09-08 2008-03-21 Univ Nagoya 高親和性ペプチドの設計法及び調製法、並びに高親和性ペプチド
US20080188618A1 (en) * 2007-01-23 2008-08-07 Greving Matthew P Porous Acrylate Copolymer Films and Uses Therefor
US20090176664A1 (en) * 2007-06-01 2009-07-09 Keting Chu High density peptide arrays containing kinase or phosphatase substrates
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
WO2010043668A1 (en) * 2008-10-17 2010-04-22 Zentech S.A. Dried blood spots for blood analysis
US9187777B2 (en) * 2010-05-28 2015-11-17 Gen9, Inc. Methods and devices for in situ nucleic acid synthesis
CA2814552A1 (en) * 2010-10-27 2012-05-03 Capitalbio Corporation Luminophore-labeled molecules coupled with particles for microarray-based assays

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020678A1 (en) * 2002-10-30 2007-01-25 Dana Ault-Riche Methods for producing polypeptide-tagged collections and capture systems containing the tagged polypeptides
US20120190574A1 (en) * 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling
WO2011109440A1 (en) * 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics

Also Published As

Publication number Publication date
WO2014036312A8 (en) 2015-04-09
WO2014036312A2 (en) 2014-03-06
EP2890984A4 (en) 2016-05-25
EP2890984B1 (en) 2018-10-03
AU2019204047B2 (en) 2021-08-05
CN104781668A (zh) 2015-07-15
CA2882801C (en) 2022-01-18
JP6873950B2 (ja) 2021-05-19
AU2019204047C1 (en) 2021-11-18
CA2882801A1 (en) 2014-03-06
CN108957005A (zh) 2018-12-07
US20200256861A1 (en) 2020-08-13
US20140087963A1 (en) 2014-03-27
AU2019204047A1 (en) 2019-06-27
GB201504970D0 (en) 2015-05-06
WO2014036312A3 (en) 2015-05-14
JP2015535336A (ja) 2015-12-10
AU2013308682A1 (en) 2015-03-12
JP2019012072A (ja) 2019-01-24
CN104781668B (zh) 2018-07-24
JP6463678B2 (ja) 2019-02-06
EP2890984A2 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
GB2525743A (en) Immunosignaturing: a path to early diagnosis and health monitoring
WO2015013214A3 (en) Methods and systems for microbiome characterization, monitoring and treatment
WO2016094904A8 (en) Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
EP2731546A4 (en) NECKLACE FOR DOMESTIC ANIMALS FOR MONITORING HEALTH AND VITAL SIGNS, GIVING THE ALERT AND PERMITTING A DIAGNOSIS
IL222251A0 (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders
MX339709B (es) Antagonistas de wnt y metodos de tratamiento y analisis.
EP2961336A4 (en) DEVICE, METHOD AND SYSTEM FOR AUTOMATED, NON-INVASIVE CELL ACTIVITY TRACKING
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
WO2014127065A3 (en) Facial expression measurement for assessment, monitoring, and treatment evaluation of affective and neurological disorders
EP3359032A4 (en) METHOD AND DEVICE FOR DETECTING AND CLASSIFYING SUITABLE ACTIVITY
EA201391187A1 (ru) Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток
EP3186397C0 (en) USE OF BIOMARKERS OF CIRCULATING CELLS IN THE BLOOD FOR THE DETECTION AND DIAGNOSIS OF DISEASES, AND THEIR ISOLATION PROCESSES
GB201011816D0 (en) Feature characterization for breathing monitor
WO2007098070A3 (en) Non-invasive methods for evaluating retinal affecting neurodegenerative diseases
EP2893030A4 (en) Diagnosis and treatment of invasive aspergillosis
DE102017010318B8 (de) Ösophaguselektrodensonde und Vorrichtung zur kardiologischen Behandlung und/oder Diagnose
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
WO2014052685A3 (en) Devices and methods for single cell analysis
WO2013087929A3 (de) Verfahren zur identifizierung von markersequenzen für gynäkologisches malignom
MX370570B (es) Marcador para trastornos de la esfingomielinasa acida y sus usos.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
EA201201482A1 (ru) Селективные ингибиторы интегрина
WO2012078648A3 (en) Novel method of cancer diagnosis and prognosis and prediction of response to therapy
AU2015268674A1 (en) Spectral sensing of ablation
EP3040026A4 (en) DIAGNOSTIC APPARATUS AND METHOD FOR BIOLOGICAL TISSUE

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)